Submitted to: USDA Interagency Research Forum on Gypsy Moth and Other Invasive Species
Publication Type: Abstract Only
Publication Acceptance Date: 9/25/2002
Publication Date: N/A
Citation: N/A Interpretive Summary:
Technical Abstract: Technical Abstract: Gypcheck ( a gypsy moth nuclear polyhedrosis virus product) has been registered for use against the gypsy moth. Environmental concerns over the effects of non-specific insecticides applied to forest ecosystems have stimulated interest in the use of Gypcheck. Gypcheck,as currently produced in vivo, has some limitations. It is expensive to produce, contains extraneous material, ans lacks potency at affordable dosages. A strain (strain 203) has been developed that is as potent as the strain LDP 226 currently used in Gypcheck, kills a bit faster, and is stable in cell culture. Its use would result in a clean product with the potential for industrial- scale production at reduced cost. Reduced cost would permit a higher dosage application that should result in improved efficacy. We designed a study that compared in-vivo produced strain LDP226 against strain 203 produced by three different methods. All strains were tested at two doses. All of the above combinations were applied with or without an adjuvant, Carrier 038, and all the above were evaluated as 1-hour, 1-day, and 2-day residues. We concluded that in-vitro produced 203 was equivalent in potency to in-vivo produced LDP226. Any affect of production method on potency of stain 203 was minor. Product potency (either strain produced by any method) was greatly enhanced when applied with Carrier 038. Carrier 038 provided excellent protection from sunlight for at least 2 days.